Advertisement
  • Yahoo Life UK

    How to get a good night's sleep with hay fever

    As hay fever symptoms spike, here's how to set the right bedtime routine. Plus how to keep pollen out of the room you sleep in.

  • Reuters

    Therapy developer Alumis seeks up to $1 billion valuation in US IPO

    Biotech IPOs have shown signs of a rebound this year, but a string of poor post-debut performances have tempered expectations of a full market recovery. It is looking to raise up to $317.7 million in the IPO by offering nearly 17.7 million shares at a price range of $16 and $18 each. South San Francisco, California-based Alumis will enter the market on the heels of therapy developer Rapport Therapeutics' strong market debut earlier this month.

  • Benzinga

    FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation

    Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) res